Countdown to Ethereum Pectra Upgrade Activation: Learn more
$2.72T
Total marketcap
$49.11B
Total volume
BTC 60.07%     ETH 7.79%
Dominance

Erasca ERAS Stock

1.16 USD {{ price }} -4.132237% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
328.59M USD
LOW - HIGH [24H]
1.09 - 1.21 USD
VOLUME [24H]
3.2M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-0.69 USD

Erasca Price Chart

Erasca ERAS Financial and Trading Overview

Erasca stock price 1.16 USD
Previous Close 1.92 USD
Open 1.93 USD
Bid 1.84 USD x 600
Ask 1.9 USD x 300
Day's Range 1.77 - 1.97 USD
52 Week Range 1.64 - 3.45 USD
Volume 2.21M USD
Avg. Volume 1.46M USD
Market Cap 525.87M USD
Beta (5Y Monthly) 1.161
PE Ratio (TTM) N/A
EPS (TTM) -0.69 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 5 USD

ERAS Valuation Measures

Enterprise Value 170.78M USD
Trailing P/E N/A
Forward P/E -2.5135136
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 1.125908
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -1.132

Trading Information

Erasca Stock Price History

Beta (5Y Monthly) 1.161
52-Week Change 9.41%
S&P500 52-Week Change 22.67%
52 Week High 3.45 USD
52 Week Low 1.64 USD
50-Day Moving Average 2.71 USD
200-Day Moving Average 2.57 USD

ERAS Share Statistics

Avg. Volume (3 month) 1.46M USD
Avg. Daily Volume (10-Days) 1.53M USD
Shares Outstanding 282.73M
Float 215.94M
Short Ratio 24.05
% Held by Insiders 12.38%
% Held by Institutions 87.02%
Shares Short 32.79M
Short % of Float 13.17%
Short % of Shares Outstanding 11.60%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2023
Most Recent Quarter (mrq) September 30, 2024
Next Fiscal Year End December 31, 2024

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) N/A
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) N/A
EBITDA -150906000 USD
Net Income Avi to Common (ttm) -159119008 USD
Diluted EPS (ttm) -0.79
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 408.41M USD
Total Cash Per Share (mrq) 1.45 USD
Total Debt (mrq) 53.97M USD
Total Debt/Equity (mrq) 11.96 USD
Current Ratio (mrq) N/A
Book Value Per Share (mrq) 1.652

Cash Flow Statement

Operating Cash Flow (ttm) N/A
Levered Free Cash Flow (ttm) N/A

Profile of Erasca

Country United States
State CA
City San Diego
Address 3115 Merryfield Row
ZIP 92121
Phone 858 465 6511
Website https://www.erasca.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 126

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Q&A For Erasca Stock

What is a current ERAS stock price?

Erasca ERAS stock price today per share is 1.16 USD.

How to purchase Erasca stock?

You can buy ERAS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Erasca?

The stock symbol or ticker of Erasca is ERAS.

Which industry does the Erasca company belong to?

The Erasca industry is Biotechnology.

How many shares does Erasca have in circulation?

The max supply of Erasca shares is 283.27M.

What is Erasca Price to Earnings Ratio (PE Ratio)?

Erasca PE Ratio is now.

What was Erasca earnings per share over the trailing 12 months (TTM)?

Erasca EPS is -0.69 USD over the trailing 12 months.

Which sector does the Erasca company belong to?

The Erasca sector is Healthcare.

Erasca ERAS included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 15587.79 USD
-5.82
9.14B USD 15575.68 USD 16128.16 USD 9.14B USD
NASDAQ Global Select Market Com NQGS 7625.89 USD
-5.84
7621.56 USD 7894.21 USD
NASDAQ Biotechnology NBI 3904.12 USD
-5.49
3901.51 USD 4064.61 USD
NASDAQ HealthCare IXHC 869.8 USD
-5.51
868.74 USD 900.72 USD
Stlmt ID NASDAQ Biotechnology NBX 4153.28 USD
+1.21
4281.91 USD 4648.11 USD